Close



May 5, 2023 06:47AM
May 5, 2023 06:46AM
May 4, 2023 06:50AM
Feb 27, 2023 06:30AM
Feb 24, 2023 09:16AM
Feb 24, 2023 09:15AM
Jan 3, 2023 06:52AM Protalix BioTherapeutics (PLX) Issues 2023 Letter to Stockholders
Jan 3, 2023 06:50AM
Dec 5, 2022 06:53AM
Dec 5, 2022 06:50AM
Mar 30, 2021 06:50AM
Dec 30, 2020 06:50AM
Dec 30, 2020 06:04AM
Dec 30, 2020 06:00AM Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Di
Nov 27, 2020 06:51AM
Nov 27, 2020 06:50AM
Oct 29, 2020 06:50AM
Oct 2, 2020 08:00AM
Oct 2, 2020 08:00AM
Sep 8, 2020 06:55AM
Aug 24, 2020 06:51AM Protalix BioTherapeutics (PLX) Reports Complete Treatment Period for Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for Proposed Treatment of Fabry Disease
Aug 24, 2020 06:50AM
Aug 11, 2020 06:52AM
Aug 11, 2020 06:50AM
Jan 2, 2018 09:06AM
Oct 13, 2015 09:29AM

12,341 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All